A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection

Journal of Viral Hepatitis

Volumn 6, Issue 5, 1999, Pages 387-395

  Gilson, R J C ^a,b,f   Chopra, K B ^c   Newell, A M ^d   Murray Lyon, I M ^c   Nelson, M R ^d   Rice, S J ^a   Tedder, R S ^a   Toole, J ^e   Jaffe, H S ^e   Weller, I V D ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b CAMDEN AND ISLINGTON NHS FOUNDATION TRUST   (United Kingdom)

^c CHARING CROSS HOSPITAL   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^e GILEAD SCIENCES   (United States)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiviral; Hepatitis B; Randomized controlled trial; Treatment

Indexed keywords

ADEFOVIR DIPIVOXIL; PLACEBO; VIRUS DNA;

ABDOMINAL PAIN; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SCREENING; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SUPERINFECTION; VIRUS DETECTION;

ADENINE; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; MALE; PHOSPHONIC ACIDS; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 0032885698     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1999.00182.x     Document Type: Article

References (37)

1. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-356.
2. Benhamou Y, Dohin E, Lunel Fabiani F et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 1995; 345: 396-397.
3. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-1661.
4. Benhamou Y, Katlama C, Lunel F et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996; 125: 705-712.
5. Lai CL, Ching CK, Tung AK et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997; 25: 241-244.
6. Cirelli R, Herne K, McCrary M, Lee P, Tyring SK. Famciclovir: review of clinical efficacy and safety. Antiviral Res 1996; 29: 141-151.
7. Main J, Brown JL, Howells C et al. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hep 1996; 3: 211-215.
8. Trepo C, Jezek P, Atkinson GF, Boon RJ. Efficacy of famciclovir in chronic hepatitis B: results of a dose finding study. Hepatology 1996; 24: 188A (abstr).
9. Dienstag JL, Schiff ER, Mitchell M et al. Extended lamivudine retreatment for chronic hepatitis B. Hepatology 1996; 24: 188A (abstr).
10. Honkoop P, de Man RA, Zondervan PE, Schalm SW. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 1997; 17: 103-106.
11. Aye TT, Bartholomeusz A, Shaw T et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997; 26: 1148-1153.
12. De Clercq E, Sakuma T, Baba M et al. Antiviral activity of phosphonylmethoxyalkyl derivatives of purines and pyrimidines. Antiviral Res 1987; 8: 261-272.
13. Pauwels R, Balzarini J, Schols D et al. Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob Agents Chemother 1988; 32: 1025-1030.
14. Yokota T, Mochizuki S, Konno K, Mori S, Shigeta S, De Clercq E. Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis. Antimicrob Agents Chemother 1991; 35: 394-397.
15. Heijtink RA, de Wilde GA, Kruining J et al. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res 1993; 21: 141-153.
16. Nicoll AJ, Colledge DL, Wang YY et al. PMEA, an acyclic phosphonate nucleoside analogue with activity against duck hepatitis B virus in vivo. Hepatology 1996; 24: 220A (abstr).
17. Cherrington JM, Allen SJ, McKee BH, Chen MS. Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine, ddCTP, AZTTP, and FIAUTP with human DNA polymerases beta and gamma. Biochem Pharmacol 1994; 48: 1986-1988.
18. Locarnini SA, Civitico GM, Newbold JE. Hepatitis B: new approaches for antiviral chemotherapy. Antiviral Chem Chemother 1996; 7: 53-64.
19. Calio R, Villani N, Balestra E et al. Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antiviral Res 1994; 23: 77-89.
20. Barditch Crovo P, Toole J, Hendrix CW et al. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. J Infect Dis 1997; 176: 406-413.
21. Decks SG, Collier A, Lalezari J et al. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis 1997; 176: 1517-1523.
22. Holme E, Greter J, Jacobson CE et al. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet 1989; 2: 469-473.
23. Ferns RB, Tedder RS. Detection of both hepatitis B e antigen and antibody in a single assay using monoclonal reagents. J Virol Methods 1985; 11: 231-239.
24. Jeffers L, Heathcote E, Wright T et al. A phase II dose-ranging, placebo-controlled trial of adefovir dipivoxil for the treatment of chronic hepatitis B virus infection. Eleventh International Conference on Antiviral Research. San Diego, CA. April 4-10, 1998 (Late-breaker abstract).
25. Alexander GJ, Brahm J, Fagan EA et al. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 1987; 2: 66-69.
26. Hoofnagle JH, Peters M, Mullen KD et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 1318-1325.
27. Honkoop P, de Man RA, Heijtink RA, Schalm SW. Hepatitis B reactivation after lamivudine. Lancet 1995; 346: 1156-1157.
28. Weller IV, Lok AS, Mindel A et al. Randomised controlled trial of adenine arabinoside 5′-monophosphate (ARA-AMP) in chronic hepatitis B virus infection. Gut 1985; 26: 745-751.
29. Ling R, Mutimer D, Ahmed M et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711-713.
30. Naoumov NV, Chokshi S, Smith HM, Williams R. Emergence and characterisation of lamivudine-resistant hepatitis B virus variant. Hepatology 1996; 24: 282A (abstr).
31. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714-717.
32. Bartholomew MM, Jansen RW, Jeffers LJ et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20-22.
33. Xiong X, Flores C, Gibbs C, Toole J. Lack of cross-resistance to PMEA for human hepatitis B DNA polymerases which express lamivudine resistance codons. Hepatology 1997; 26: 431A (abstr).
34. Gu Z, Salomon H, Cherrington JM et al. K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl) adenine. Antimicrob Agents Chemother 1995; 39: 1888-1891.
35. Cherrington JM, Mulato AS, Fuller MD, Chen MS. Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro. Antimicrob Agents Chemother 1996; 40: 2212-2216.
36. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997; 26: 216-225.
37. Shaw T, Colledge D, Locarnini S. Synergistic inhibition of hepadnaviral replication by PMEA and penciclovir or lamivudine in combination in vitro. (abstr). Antiviral Res 1997; 34.